title: Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment.
abstract: Chemotherapy is one major approach for treating non-small cell lung carcinoma (NSCLC). However, the progression-free survival rate depends on whether there is tumor metastasis after drug treatment. The biological behavior for its characteristics remains to be clarified. Here, we treated A549 and H1299 NSCLC cell lines with cisplatin, doxorubicin and gemcitabine at the IC(50) dose. Most attached cells were surviving cells (A549-A and H1299-A), whereas only a small portion of detached cells survived and reattached to tissue culture plates (A549-R and H1299-R) for further growth. Using cisplatin, a series of H1299 sublines (H1299-R2∼H1299-R5) were also generated by the same selection procedure. Drug treatment increased the migratory ability of A549-R and H1299-R cells. A serial selection could enhance the invasiveness of cells. Cisplatin treatment inhibited the adhesion ability of H1299-R cells compared with their H1299 and H1299-A counterparts. H1299-R cells exhibited increased drug resistance to cisplatin and increased expression of ABCG2, CD133 and CD44. Compared with mice subcutaneously injected with H1299 cells, mice subcutaneously injected with H1299-R cells showed an increase in the number of metastatic lung nodules. We conclude that H1299-R cells selected by suboptimal doses of cisplatin following detachment from and reattachment to the tissue culture plate acquire an enhanced malignant phenotype. Therefore, they provide a more faithful lung cancer model associated with biological aggressiveness for studying clinically recurrent cancers after chemotherapy.
authors.affiliation: Department of Nursing, Chung Hwa University of Medical Technology, Tainan Hsien, Taiwan.
authors.forename: Jeng-Long
authors.initials: JL
authors.lastname: Hsieh
authors.forename: Chia-Sing
authors.initials: CS
authors.lastname: Lu
authors.forename: Chin-Ling
authors.initials: CL
authors.lastname: Huang
authors.forename: Gia-Shing
authors.initials: GS
authors.lastname: Shieh
authors.forename: Bing-Hua
authors.initials: BH
authors.lastname: Su
authors.forename: Yu-Chu
authors.initials: YC
authors.lastname: Su
authors.forename: Che-Hsin
authors.initials: CH
authors.lastname: Lee
authors.forename: Meng-Ya
authors.initials: MY
authors.lastname: Chang
authors.forename: Chao-Liang
authors.initials: CL
authors.lastname: Wu
authors.forename: Ai-Li
authors.initials: AL
authors.lastname: Shiau
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology*; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D002945:Cisplatin / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin